SLC18A2 and Menkes disease: TBZ depletes vesicular stores of dopamine by inhibiting the vesicular monoamine transporter 2 (VMAT‐2) and is another effective drug for the treatment of dystonia as well as other hyperkinetic MD, such as chorea, tics, tardive dyskinesia, and myoclonus (Kenney et al., 2007).